抗血管生成抑制剂在伴或不伴恶性肿瘤患者中的血栓与出血风险
本文为叙述性综述,描述已获批抗血管生成药物相关的静脉血栓栓塞、动脉血栓形成及出血风险的文献证据。文章指出不同类别甚至同类不同药物间风险差异显著,并讨论了在癌症治疗及遗传性出血性毛细血管扩张症、新生血管性年龄相关性黄斑变性等非恶性疾病管理中的这些并发症。
要点
- 抗血管生成治疗中血栓与出血风险是重要临床关注点。
- 静脉血栓栓塞、动脉血栓形成及出血风险在不同类别及同类不同药物间差异显著。
- 风险讨论需结合癌症治疗与非恶性疾病(如HHT、nAMD)管理背景。
核心结论
- 抗血管生成药物的静脉血栓栓塞、动脉血栓形成及出血风险在不同类别及同类不同药物间存在显著差异。
研究设计与样本
- 叙述性综述,描述研究现有抗血管生成药物相关静脉与动脉血栓及出血风险的文献。
主要发现
- 过去二十年抗血管生成治疗已发展为癌症治疗的主要类别,美国已批准16种抗血管生成药物用于癌症治疗。
- VEGF家族信号蛋白及其受体是该类治疗的主要靶点。
- 血栓与出血并发症是重要临床关注点,可能影响伴或不伴癌症且已存在血栓/出血风险升高患者的使用。
临床怎么用
- 评估抗血管生成治疗时需考虑静脉血栓栓塞、动脉血栓形成及出血风险,并注意不同药物间风险差异。
- 需在癌症治疗及非恶性疾病(如遗传性出血性毛细血管扩张症、新生血管性年龄相关性黄斑变性)管理中关注这些并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the past two decades, therapies targeting angiogenesis have developed into a major class of cancer therapeutics. The vascular endothelial growth factor (VEGF) family of signaling proteins, a group of potent angiogenic growth factors, and their receptors represent the main targets of this therapeutic class. To date, 16 antiangiogenic agents have been approved in the United States for the treatment of cancer and several more are in development. An important consideration with antiangiogenic therapy is toxicity, in particular thrombotic and bleeding risks. These complications have emerged as a major clinical concern that may affect the use of these agents in patients both with and without cancer who may already have an elevated risk of thrombosis and bleeding. Although these agents are frequently considered together as a class when contemplating their bleeding and thrombotic risks, in fact the risks for venous thromboembolism, arterial thrombosis, and bleeding vary significantly between different classes of antiangiogenic agents and even among different agents within a class. In this narrative review, we describe the literature investigating the venous and arterial thrombotic and bleeding risks associated with the currently available antiangiogenic drugs. In addition, we discuss these specific complications in the context of both cancer therapy as well as the management of nonmalignant disorders now managed with antiangiogenic agents, including hereditary hemorrhagic telangiectasia and neovascular age-related macular degeneration.
引用
- Watson N, Al-Samkari H. Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy. J Thromb Haemost. 2021. PMID: 33928747. doi:10.1111/jth.15354
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。